Sylvia Nikkho
About
Sylvia Nikkho is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Genetics.
According to data from OpenAlex, Sylvia Nikkho has authored 33 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 15 papers in Cardiology and Cardiovascular Medicine and 6 papers in Genetics. Recurrent topics in Sylvia Nikkho's work include Pulmonary Hypertension Research and Treatments (29 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers) and Heart Failure Treatment and Management (8 papers). Sylvia Nikkho is often cited by papers focused on Pulmonary Hypertension Research and Treatments (29 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers) and Heart Failure Treatment and Management (8 papers). Sylvia Nikkho collaborates with scholars based in Germany, United States and United Kingdom. Sylvia Nikkho's co-authors include Hossein Ardeschir Ghofrani, Marius M. Hoeper, Christian Meier, Friedrich Grimminger, Gérald Simonneau, Eckhard Mayer, Pavel Jansa, Arno Fritsch, Joanna Pepke‐Żaba and Ekkehard Grünig and has published in prestigious journals such as CHEST Journal, Annals of the Rheumatic Diseases and European Respiratory Journal.
In The Last Decade
Sylvia Nikkho
31 papers receiving 610 citations
Peers
Sylvia Nikkho
R.F. Roscigno United States
Qixian Zeng China
J.-L. Jagot France
H. James Ford United States
Martha Kingman United States
Michela Efficace Switzerland
Paul Sephton United Kingdom
Ryotaro Asano Japan
Katcharin Aryurachai Thailand
Citations per year, relative to Sylvia Nikkho Sylvia Nikkho (= 1×)
peers
R.F. Roscigno
Countries citing papers authored by Sylvia Nikkho
Since
Specialization
Citations
This map shows the geographic impact of Sylvia Nikkho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvia Nikkho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvia Nikkho more than expected).
Fields of papers citing papers by Sylvia Nikkho
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sylvia Nikkho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvia Nikkho. The network helps show where Sylvia Nikkho may publish in the future.
Co-authorship network of co-authors of Sylvia Nikkho
This figure shows the co-authorship network connecting the top 25 collaborators of Sylvia Nikkho. A scholar is included among the top collaborators of Sylvia Nikkho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvia Nikkho. Sylvia Nikkho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Saleh, Soundos, et al.. (2025). Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat (BAY 1237592): Results from Randomized Phase I Studies in Healthy Men. Clinical Pharmacokinetics. 64(6). 909–924.
2.
Vitulo, Patrizio, Lucilla Piccari, Stephen J. Wort, et al.. (2024). Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH‐CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative—group 3 pulmonary hypertension. Pulmonary Circulation. 14(4). e70005–e70005.
3.
Piccari, Lucilla, Brian Allwood, Katerina Antoniou, et al.. (2023). Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative ‐ Group 3 Pulmonary Hypertension. Pulmonary Circulation. 13(2). e12213–e12213.
4.
Nikkho, Sylvia, Manuel J. Richter, Eric Shen, et al.. (2022). Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension. Pulmonary Circulation. 12(3). e12127–e12127.
5.
Benza, Raymond L., Harrison W. Farber, Adaani Frost, et al.. (2022). Application of the REVEAL risk score calculator 2.0 in the CHEST study. Respiratory Medicine. 195. 106783–106783.
6.
Hahn, Michael G., Martina Delbeck, Lisa Dietz, et al.. (2022). Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC. Respiratory Research. 23(1). 272–272.
7.
Benza, Raymond L., Athénaïs Boucly, Harrison W. Farber, et al.. (2021). Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study. The Journal of Heart and Lung Transplantation. 41(3). 411–420.
8.
Benza, Raymond L., Harrison W. Farber, Adaani Frost, et al.. (2021). Application of the REVEAL risk score calculator 2.0 in the PATENT study. International Journal of Cardiology. 332. 189–192.
9.
Nathan, Steven D., Vincent Cottin, Jürgen Behr, et al.. (2021). Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. The Journal of Heart and Lung Transplantation. 40(6). 494–503.
10.
Sitbon, Olivier, Sylvia Nikkho, Raymond L. Benza, et al.. (2020). Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. Pulmonary Circulation. 10(4). 1–11.
11.
Benza, Raymond L., Harrison W. Farber, Adaani Frost, et al.. (2018). REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. The Journal of Heart and Lung Transplantation. 37(7). 836–843.
12.
Halank, Michael, Marius M. Hoeper, Hossein Ardeschir Ghofrani, et al.. (2017). Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respiratory Medicine. 128. 50–56.
13.
McLaughlin, Vallerie V., Pavel Jansa, Jens Erik Nielsen‐Kudsk, et al.. (2017). Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulmonary Medicine. 17(1). 216–216.
14.
Benza, Raymond L., Harrison W. Farber, Adaani Frost, et al.. (2017). REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. The Journal of Heart and Lung Transplantation. 37(4). 513–519.
15.
Mathai, Stephen C., Hossein Ardeschir Ghofrani, Eckhard Mayer, et al.. (2016). Quality of life in patients with chronic thromboembolic pulmonary hypertension. European Respiratory Journal. 48(2). 526–537.
16.
Wang, Chen, Zhi‐Cheng Jing, Yigao Huang, et al.. (2016). Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison. Heart Asia. 8(1). 74–82.
17.
Ghofrani, Hossein Ardeschir, Friedrich Grimminger, Ekkehard Grünig, et al.. (2016). Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. The Lancet Respiratory Medicine. 4(5). 361–371.
18.
Hassoun, Paul M., Sylvia Nikkho, & Ronald J. Oudiz. (2013). Updating Clinical Endpoints in Pulmonary Arterial Hypertension: When Challenges are Welcome. Pulmonary Circulation. 3(3). 721–722.
19.
Hassoun, Paul M., Sylvia Nikkho, Erika B. Rosenzweig, et al.. (2013). Updating Clinical Endpoint Definitions. Pulmonary Circulation. 3(1). 206–216.
20.
Olschewski, Horst, Marius M. Hoeper, Jürgen Behr, et al.. (2010). Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respiratory Medicine. 104(5). 731–740.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by R.F. Roscigno Breakdown of academic impact, for papers by Qixian Zeng Breakdown of academic impact, for papers by J.-L. Jagot Breakdown of academic impact, for papers by H. James Ford Breakdown of academic impact, for papers by Martha Kingman Breakdown of academic impact, for papers by Michela Efficace Breakdown of academic impact, for papers by Paul Sephton Breakdown of academic impact, for papers by Ryotaro Asano Breakdown of academic impact, for papers by Katcharin Aryurachai Breakdown of academic impact, for papers by Katarzyna Ptaszyńska‐Kopczyńska